Orthocell Investor Centre
Orthocell is a publicly-traded company listed on the Australian Securities Exchange (ASX:OCC).
Advanced portfolio with significant clinical evidence and near-term commercial milestones.
GMP-certified and TGA-licensed manufacturing facility.
Comprehensive global patent portfolio.
Highly experienced board and management team.
. To view a full summary of the Company’s current performance on the ASX click here
“Our Company is pursuing a total addressable market for our dental, nerve and autologous tendon therapy products of US$17.7 billion per annum – a compelling investment and growth opportunity.”
Orthocell MD, Paul Anderson
Latest news
Orthocell achieves first Remplir™ sales in US$75 million Canadian Market
Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device. The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide the majority of national coverage across the Canadian market and position […]
Orthocell reports continued growth and strong US momentum in March 2026 quarter
Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial traction in the United States, and expanding global adoption of Remplir™.
First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network
Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems.